Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin plus weekly paclitaxel and low-dose gemcitabine versus standard of care in metastatic pancreatic cancer after chemotherapy failure
2019-002553-35Phase 2Active
- Sponsor
- 1Globe Health Institute
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) comparing Napabucasin combination arm with Standard of care treatment options (2 arms). Started Jun 2020; status: active.
02
Drugs
napabucasin
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2019-002553-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002553-35.